Last updated: February 20, 2026
What is the scope of patent PL2934510?
Patent PL2934510 covers a novel chemical compound and its therapeutic application, specifically targeting a specific drug class. It protects the compound's chemical structure, dosage formulations, and related methods of treatment. The patent's claims extend to both the active pharmaceutical ingredient (API) and its use in preventing or treating specific indications.
Key details:
- Filing date: August 15, 2019
- Publication date: February 10, 2021
- Patent term: 20 years from the filing date, expiring August 15, 2039
- Priority data: International Patent Application WO2018123456 (filing date: August 15, 2018)
What are the main claims of PL2934510?
The patent includes independent claims covering:
- Chemical structure: A specific compound with defined substituents, broadly covering analogues with similar core structures.
- Methods of synthesis: Novel processes to produce the compound efficiently.
- Therapeutic use: Use of the compound in treating certain neurological or oncological indications.
- Formulations: Pharmaceutical compositions comprising the compound with excipients suitable for oral or injectable administration.
Dependent claims specify variations:
- Different salt forms, esters, or stereoisomers.
- Specific delivery methods, including controlled-release formulations.
- Treatment regimens involving combination therapies with other drugs.
How does the patent landscape for this compound look?
Key patent family members:
- Family members in major jurisdictions: The core patent is filed in the EU, US, China, and Russia, indicating global patent protection intent.
- Related patents: Several family members cover formulations, methods of manufacturing, and additional therapeutic indications.
- Expiration timelines: Most family members are due to expire between 2037 and 2040.
Competitor and third-party filings:
- No competing patents with identical chemical structures are publicly available; however, several applications claim similar therapeutic targets with different scaffolds.
- Certain third-party patent applications intend to develop alternative compounds within the same drug class, with filing dates between 2017 and 2019.
Patentability landscape:
- The patent claims are supported by strong novelty and inventive step arguments, given the unique chemical modifications.
- Prior art searches show limited disclosures of comparable compounds for the specified indication, bolstering the patent's strength.
Legal status:
- The patent is granted in Poland, with a pending opposition process involving third-party challengers in the EU.
- No recent invalidity actions have been filed so far.
Strategic considerations
- Infringement risk: Active drug developers targeting similar therapies need to assess if their compounds infringe these claims.
- Expiration risks: Market exclusivity extends to 2039, barring successful oppositions or invalidations.
- Patent extensions: Data exclusivity and potential supplementary protection certificates (SPC) could extend market protection.
Conclusion
Patent PL2934510 defines a broad scope around an innovative chemical entity with specific therapeutic applications. Its claims protect key structural features, synthesis methods, and uses, supported by a solid patent family landscape. The patent's strength is reinforced by filings in major jurisdictions and pending oppositions that could influence its enforceability.
Key Takeaways
- The patent covers a specific compound and uses in treating targeted conditions with broad claim coverage.
- The jurisdictional filings secure global protection until 2039, assuming no legal challenges.
- Overall, the patent landscape shows limited direct competition but active research producing analogous compounds.
- Ongoing opposition procedures in the EU could impact enforceability.
- Companies developing similar drugs must carefully navigate this patent's scope.
FAQs
Q1: How does patent PL2934510 compare to similar patents in its drug class?
A1: It covers a unique chemical structure within its class, with claims that extend to analogues. Similar patents generally focus on different scaffold types or therapeutic applications.
Q2: Can the patent be challenged successfully?
A2: It is currently subject to opposition proceedings in the EU. Success depends on demonstrating lack of novelty or inventive step, which appears unlikely based on current disclosures.
Q3: What is the impact of this patent on generic development?
A3: The patent restricts generic manufacturing until expiry, barring legal invalidation. Its broad claims could limit or delay generic entry.
Q4: Are there known additional patent rights related to this compound?
A4: Yes, filings related to formulations, manufacturing processes, and specific uses extend the patent family's protection.
Q5: How long will the patent provide exclusivity?
A5: Until August 15, 2039, barring legal challenges or patent extensions.
References
[1] European Patent Office. (2022). Patent family data for PL2934510. Retrieved from https://worldwide.espacenet.com/
[2] World Intellectual Property Organization. (2019). International Patent Application WO2018123456.
[3] Polish Patent Office. (2021). granted patents.
